Nintedanib for Previously Treated Locally Advanced, Metastatic, or Locally Recurrent Non-Small-Cell Lung Cancer (TA347)

Technology Appraisal Guidance No. 347

Source: National Institute for Health and Care Excellence

1. Guidance

1.1  Nintedanib in combination with docetaxel is recommended, within its marketing authorisation, as an option for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology that has progressed after first-line chemotherapy, only if the company provides nintedanib with the discount agreed in the patient access scheme.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer

Issue Date: July 2015

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in